SG11201805888SA - Cyclic dinucleotides for treating conditions associated with sting activity such as cancer - Google Patents
Cyclic dinucleotides for treating conditions associated with sting activity such as cancerInfo
- Publication number
- SG11201805888SA SG11201805888SA SG11201805888SA SG11201805888SA SG11201805888SA SG 11201805888S A SG11201805888S A SG 11201805888SA SG 11201805888S A SG11201805888S A SG 11201805888SA SG 11201805888S A SG11201805888S A SG 11201805888SA SG 11201805888S A SG11201805888S A SG 11201805888SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cancer
- pct
- sting
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
RiA RIB L — X XZ X' X 4 X 6 —L 2 - R2A R —2B (A) R4' R4' 1 -^ 1 ^ , (iv) W O 20 17 / 123669 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/123669 Al 20 July 2017 (20.07.2017) WIPO I PCT 1111111111111101110111111111110101111101110111011101111111111111110111111111110111111 (51) International Patent Classification: C07H 21/00 (2006.01) A61P 35/00 (2006.01) A61K 31/7084 (2006.01) (21) International Application Number: PCT/US2017/013066 (22) International Filing Date: 11 January 2017 (11.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/277,273 11 January 2016 (11.01.2016) US 62/436,759 20 December 2016 (20.12.2016) US (72) Inventors; and (71) Applicants : GLICK, Gary [US/US]; 1663 Snowberry Ridge Rd., Ann Arbor, MI 48103 (US). GHOSH, Shomir [US/US]; 134 Sewall Avenue, Unit C, Brookline, MA 02446 (US). OLHAVA, Edward, James [US/US]; 11 Scarsdale Rd, Newton, MA 02460 (US). ROUSH, Willi- am, R. [US/US]; 1013 Town Hall Avenue, Jupiter, FL 33458 (US). JONES, Roger [US/US]; 65 Hillcrest Rd., Martinsville, NJ 08836 (US). (74) Agents: KENDALL, John, T. et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, MN 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [Continued on next page] (54) Title: CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER (57) : This disclosure features dinucleotide com- pounds that modulate Stimulator of Interferon Genes (STING) activity, for use for example in the treatment of cancer. This disclosure also features compositions as well as other methods of using and making the same (Fomula (A)). A and B are each independently selected from the group consisting of Formulae (i), (ii), (iii), and (iv). R 5 0 R4 -- I ,1 Z2 Z 3 1 Z i R 6 Z 2 ' Z 2 R6 (i) (ii) WO 2017/123669 Al MIDEDIMOMMIONMEMOMEMODIEHHOMEHOIS TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Published: TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, with international search report (Art. 21(3)) LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277273P | 2016-01-11 | 2016-01-11 | |
| US201662436759P | 2016-12-20 | 2016-12-20 | |
| PCT/US2017/013066 WO2017123669A1 (en) | 2016-01-11 | 2017-01-11 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805888SA true SG11201805888SA (en) | 2018-08-30 |
Family
ID=58010371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805888SA SG11201805888SA (en) | 2016-01-11 | 2017-01-11 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10604542B2 (en) |
| EP (1) | EP3402801A1 (en) |
| JP (1) | JP6867395B2 (en) |
| KR (1) | KR20180097751A (en) |
| CN (1) | CN109451740B (en) |
| AU (1) | AU2017207757B2 (en) |
| BR (1) | BR112018013808A2 (en) |
| CA (1) | CA3011528A1 (en) |
| CL (1) | CL2018001870A1 (en) |
| CO (1) | CO2018008196A2 (en) |
| EA (1) | EA036421B1 (en) |
| IL (1) | IL260427B (en) |
| MX (1) | MX2018008266A (en) |
| MY (1) | MY194058A (en) |
| PE (1) | PE20181330A1 (en) |
| SG (1) | SG11201805888SA (en) |
| WO (1) | WO2017123669A1 (en) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016145102A1 (en) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| GEP20207182B (en) | 2015-08-13 | 2020-11-25 | Merck Sharp & Dohme | Cyclic di-nucleotide compounds as sting agonists |
| AU2017207757B2 (en) * | 2016-01-11 | 2021-05-27 | Innate Tumor Immunity, Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| JP6980198B2 (en) | 2016-03-18 | 2021-12-15 | イミューン センサー リミテッド ライアビリティ カンパニー | Cyclic dinucleotide compound and usage |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| US11033569B2 (en) | 2016-07-06 | 2021-06-15 | Sperovie Biosciences, Inc. | Compounds,Compositions, and methods for the treatment of disease |
| CN110121335A (en) | 2016-08-30 | 2019-08-13 | 达纳-法伯癌症研究所股份有限公司 | Drug delivery composition and application thereof |
| EA037626B1 (en) | 2016-10-04 | 2021-04-22 | Мерк Шарп И Доум Корп. | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
| JOP20170192A1 (en) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | Cyclic dinucleotide |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| AU2018252546A1 (en) | 2017-04-13 | 2019-10-10 | Sairopa B.V. | Anti-SIRPα antibodies |
| EP3621624B1 (en) | 2017-05-12 | 2023-08-30 | Merck Sharp & Dohme LLC | Cyclic di-nucleotide compounds as sting agonists |
| US11259980B2 (en) | 2017-07-31 | 2022-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Soft inflatable exosuit for knee rehabilitation |
| US11285131B2 (en) | 2017-08-04 | 2022-03-29 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene STING agonists for cancer treatment |
| CA3071537A1 (en) | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | Combinations of pd-1 antagonists and benzo[b]thiophene sting agonists for cancer treatment |
| KR20200058411A (en) | 2017-08-30 | 2020-05-27 | 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 | Cyclic di-nucleotides as stimulators of interferon gene modulators |
| KR20200039796A (en) * | 2017-08-31 | 2020-04-16 | 브리스톨-마이어스 스큅 컴퍼니 | Cyclic dinucleotide as an anticancer agent |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | Compounds compositions, and methods for the treatment of disease |
| EP3681894A1 (en) * | 2017-09-14 | 2020-07-22 | Janssen BioPharma, Inc. | Modified nucleoside phosphoramidites |
| CN111344297B (en) * | 2017-10-10 | 2023-10-20 | 百时美施贵宝公司 | Cyclic dinucleotides as anticancer agents |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | Conjugates and methods of use thereof for selective delivery of immune-modulatory agents |
| PE20210156A1 (en) | 2017-11-10 | 2021-01-26 | Takeda Pharmaceuticals Co | STING MODULATING COMPOUNDS AND METHODS OF PREPARATION AND USE |
| CN111511754B (en) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 2'3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein |
| US11685761B2 (en) | 2017-12-20 | 2023-06-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| KR102492187B1 (en) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3' cyclic dinucleotides with phosphonate linkages that activate STING adapter proteins |
| EP3505527A1 (en) * | 2017-12-29 | 2019-07-03 | Invivogen | Cyclic dinucleotides for cytokine induction |
| US10519187B2 (en) | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| JP7250808B2 (en) * | 2018-03-08 | 2023-04-03 | ブリストル－マイヤーズ スクイブ カンパニー | Cyclic dinucleotides as anticancer agents |
| WO2019180683A1 (en) | 2018-03-23 | 2019-09-26 | Takeda Pharmaceutical Company Limited | Sting modulator compounds with sulfamate linkages, and methods of making and using |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| BR112020020085A8 (en) | 2018-04-03 | 2023-04-11 | Merck Sharp & Dohme | COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS FOR INDUCING AN IMMUNE RESPONSE, FOR INDUCING STING-DEPENDENT TYPE I INTERFERON PRODUCTION, AND FOR TREAT A CELL PROLIFERATION DISORDER |
| TWI818007B (en) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-cyclic dinucleotides |
| TWI833744B (en) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-cyclic dinucleotides |
| MA52754A (en) | 2018-05-25 | 2021-04-14 | Incyte Corp | HETEROCYCLIC TRICYCLIC COMPOUNDS AS STING ACTIVATORS |
| TW202030199A (en) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | Cyclic dinucleotides as sting agonists |
| WO2020028565A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Tricyclic heteraryl compounds as sting activators |
| WO2020028566A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| AU2019322722A1 (en) | 2018-08-16 | 2020-10-15 | Eisai R&D Management Co., Ltd. | Salts of compounds and crystals thereof |
| IL281247B1 (en) | 2018-09-06 | 2024-09-01 | Daiichi Sankyo Co Ltd | Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof |
| KR20210081332A (en) | 2018-09-12 | 2021-07-01 | 실버백 테라퓨틱스, 인크. | Compositions for Treatment of Diseases Using Immunostimulatory Conjugates |
| CA3113425A1 (en) | 2018-09-21 | 2020-03-26 | Shanghai De Novo Pharmatech Co., Ltd. | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| EP3873484B1 (en) | 2018-10-29 | 2023-08-23 | Venenum Biodesign, LLC | Novel sting agonists |
| WO2020089815A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| EA202191565A1 (en) * | 2018-12-04 | 2021-12-02 | Бристол-Маерс Сквибб Компани | METHOD FOR PRODUCING CYCLIC DINUCLEOTIDE |
| US12129267B2 (en) | 2019-01-07 | 2024-10-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| EP3921323A1 (en) * | 2019-02-05 | 2021-12-15 | Bristol-Myers Squibb Company | Synthesis of 1,2,5-tri-0-benz0yl-3-dibenzylamin0-3-de0xyrib0se as intermediate for producing 3'-amino-3'-deoxyadenosine and 3'-amino-3'-deoxyguanosine and the protected derivatives thereof |
| BR112021022514A2 (en) | 2019-05-10 | 2022-04-19 | Takeda Pharmaceuticals Co | Antibody and drug conjugates |
| CN114340680A (en) | 2019-07-05 | 2022-04-12 | 坦博公司 | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| TW202114710A (en) * | 2019-07-25 | 2021-04-16 | 英屬開曼群島商百濟神州有限公司 | Cyclic dinucleotides as sting agonists |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| KR20220122701A (en) | 2019-12-26 | 2022-09-02 | 내셔널 유니버시티 코포레이션 토카이 내셔널 하이어 에듀케이션 앤드 리서치 시스템 | Polynucleotides and pharmaceutical compositions |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US20230330248A1 (en) | 2020-03-06 | 2023-10-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
| TW202200136A (en) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | Cancer treatment method |
| WO2021216698A1 (en) * | 2020-04-21 | 2021-10-28 | Duke University | Compositions and methods for the treatment of pain |
| AU2021270347A1 (en) | 2020-05-11 | 2022-12-15 | Erytech Pharma | Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof |
| IL299508A (en) | 2020-07-01 | 2023-02-01 | Ars Pharmaceuticals Inc | Anti-asgr1 antibody conjugates and uses thereof |
| JP2023537066A (en) | 2020-08-07 | 2023-08-30 | タンボ・インコーポレイテッド | Trans-cyclooctene bioorthogonal agents and their use in cancer and immunotherapy |
| EP4209506A4 (en) | 2020-09-02 | 2024-10-09 | Daiichi Sankyo Co Ltd | Novel endo-?-n-acetylglucosaminidase |
| CN116390764A (en) * | 2020-10-15 | 2023-07-04 | 密歇根大学董事会 | Crystalline polymorphic forms of STING agonist bound to metal ions capable of modulating immune responses |
| KR102466750B1 (en) * | 2020-10-23 | 2022-11-15 | 아주대학교산학협력단 | Pharmaceutical composition comprising indolizine derivative for activating stimulator of interferon gene dependent signalling |
| US20230390409A1 (en) | 2020-10-30 | 2023-12-07 | Avacta Life Sciences Limited | Fap-activated serum extended half-life therapeutic conjugates |
| KR20230106606A (en) | 2020-11-09 | 2023-07-13 | 다케다 야쿠힌 고교 가부시키가이샤 | antibody drug conjugate |
| CA3225964A1 (en) | 2021-06-30 | 2023-01-25 | Kyowa Kirin Co., Ltd. | Polynucleotide and pharmaceutical composition |
| WO2023167238A1 (en) | 2022-03-02 | 2023-09-07 | 第一三共株式会社 | METHOD FOR PRODUCING Fc-CONTAINING MOLECULE |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| AU2003244088A1 (en) | 2002-06-20 | 2004-01-06 | Nippon Suisan Kaisha, Ltd. | Produrg, medicinal utilization thereof and process for producing the same |
| AU2005222626B2 (en) * | 2004-03-15 | 2010-05-20 | Karagen Pharmaceuticals, Inc. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| SG11201407875UA (en) | 2012-06-08 | 2014-12-30 | Aduro Biotech | Compostions and methods for cancer immunotherapy |
| PT2931738T (en) | 2012-12-13 | 2019-04-10 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| US9840533B2 (en) * | 2013-04-29 | 2017-12-12 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| SG11201508273RA (en) | 2013-05-18 | 2015-12-30 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| CN109394752A (en) | 2013-10-21 | 2019-03-01 | 德雷克塞尔大学 | The purposes for treating the STING agonist of chronic HBV infection |
| EP3071209A4 (en) | 2013-11-19 | 2017-08-16 | The University of Chicago | Use of sting agonist as cancer treatment |
| WO2015077534A1 (en) | 2013-11-22 | 2015-05-28 | Massachusetts Institute Of Technology | Photovoltaic power balancing and differential power processing |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| EP3233191A1 (en) | 2014-12-16 | 2017-10-25 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| US10011630B2 (en) | 2014-12-16 | 2018-07-03 | Invivogen | Cyclic dinucleotides for cytokine induction |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016145102A1 (en) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
| GEP20207182B (en) | 2015-08-13 | 2020-11-25 | Merck Sharp & Dohme | Cyclic di-nucleotide compounds as sting agonists |
| RU2020113165A (en) | 2015-12-03 | 2020-06-09 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | CYCLIC PURINE DINUCLEOTIDES AS STING MODULATORS |
| AU2017207757B2 (en) * | 2016-01-11 | 2021-05-27 | Innate Tumor Immunity, Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| JP6980198B2 (en) | 2016-03-18 | 2021-12-15 | イミューン センサー リミテッド ライアビリティ カンパニー | Cyclic dinucleotide compound and usage |
-
2017
- 2017-01-11 AU AU2017207757A patent/AU2017207757B2/en active Active
- 2017-01-11 JP JP2018536116A patent/JP6867395B2/en active Active
- 2017-01-11 US US15/748,685 patent/US10604542B2/en active Active
- 2017-01-11 EP EP17704338.7A patent/EP3402801A1/en active Pending
- 2017-01-11 MY MYPI2018702369A patent/MY194058A/en unknown
- 2017-01-11 WO PCT/US2017/013066 patent/WO2017123669A1/en active Application Filing
- 2017-01-11 KR KR1020187022863A patent/KR20180097751A/en not_active Application Discontinuation
- 2017-01-11 MX MX2018008266A patent/MX2018008266A/en unknown
- 2017-01-11 CN CN201780015198.2A patent/CN109451740B/en active Active
- 2017-01-11 SG SG11201805888SA patent/SG11201805888SA/en unknown
- 2017-01-11 EA EA201891565A patent/EA036421B1/en not_active IP Right Cessation
- 2017-01-11 PE PE2018001267A patent/PE20181330A1/en unknown
- 2017-01-11 BR BR112018013808-8A patent/BR112018013808A2/en active Search and Examination
- 2017-01-11 CA CA3011528A patent/CA3011528A1/en active Pending
-
2018
- 2018-07-04 IL IL260427A patent/IL260427B/en active IP Right Grant
- 2018-07-10 CL CL2018001870A patent/CL2018001870A1/en unknown
- 2018-08-02 CO CONC2018/0008196A patent/CO2018008196A2/en unknown
-
2020
- 2020-01-31 US US16/778,281 patent/US10961270B2/en active Active
-
2021
- 2021-01-28 US US17/160,578 patent/US11505571B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017207757B2 (en) | 2021-05-27 |
| US20210147467A1 (en) | 2021-05-20 |
| US11505571B2 (en) | 2022-11-22 |
| BR112018013808A2 (en) | 2018-12-11 |
| US20190016750A1 (en) | 2019-01-17 |
| MY194058A (en) | 2022-11-10 |
| JP6867395B2 (en) | 2021-04-28 |
| US20200165288A1 (en) | 2020-05-28 |
| KR20180097751A (en) | 2018-08-31 |
| AU2017207757A1 (en) | 2018-08-23 |
| EA036421B1 (en) | 2020-11-09 |
| CL2018001870A1 (en) | 2018-11-30 |
| CO2018008196A2 (en) | 2018-08-10 |
| MX2018008266A (en) | 2019-01-31 |
| IL260427B (en) | 2021-03-25 |
| EA201891565A1 (en) | 2019-01-31 |
| EP3402801A1 (en) | 2018-11-21 |
| PE20181330A1 (en) | 2018-08-20 |
| CN109451740B (en) | 2022-09-02 |
| JP2019501204A (en) | 2019-01-17 |
| NZ745066A (en) | 2024-05-31 |
| US10604542B2 (en) | 2020-03-31 |
| CA3011528A1 (en) | 2017-07-20 |
| CN109451740A (en) | 2019-03-08 |
| WO2017123669A1 (en) | 2017-07-20 |
| US10961270B2 (en) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones |